Ketamine Improved Nearly Every Depression Symptom Within Hours. The Hard Part Is Making It Last

Health Science Hub Editorial

Evidence review & editorial synthesis

For decades, one of the frustrating realities of antidepressant treatment was time.

A medication could take weeks before doctors knew whether it was working, and patients with severe depression sometimes had to repeat that process several times.

Ketamine changed that expectation.

A new pooled analysis of two randomized controlled trials now shows just how broad its early effect can be. Among 132 people with treatment-resistant depression, a single intravenous dose of ketamine at 0.5 mg/kg significantly improved 9 of the 10 individual symptoms measured by the Montgomery-Åsberg Depression Rating Scale after only four hours.

The improvement was not confined to sadness. It included pessimistic thinking and suicidal thoughts, and all four broader symptom domains examined by the researchers improved at four hours and remained significantly better at day 2.

The finding adds another piece to one of modern psychiatry's most unusual treatment stories: a drug originally developed as an anesthetic can alter severe depressive symptoms on a timescale measured in hours rather than weeks.

Nearly the whole symptom profile moved at once

Depression scores usually combine many different experiences into a single number. That can hide an important question.

Does a treatment improve one or two symptoms strongly enough to drag the total score downward, or does the depressive state change more broadly?

The new study tried to answer that by looking separately at each of the 10 MADRS items.

The researchers pooled 132 participants from two randomized trials, with 66 assigned to ketamine and 66 to protocol-specific control conditions. Four hours after treatment, 9 of the 10 symptoms met the study's multiple-comparison threshold for a ketamine benefit.

Among the clearest individual differences were apparent sadness, pessimistic thoughts and suicidal thoughts. Each showed an adjusted advantage of roughly 1.1 points on its MADRS item compared with control treatment.

The researchers also grouped symptoms into four broader domains derived from previous literature. All four domains showed significant benefits at four hours and again at day 2.

That makes the result more interesting than a simple improvement in total depression score. At least acutely, ketamine appeared to produce a broad shift across the depressive syndrome.

The exploratory network analysis was much less definitive. Some relationships between symptoms changed after treatment, but the results depended on statistical thresholds and did not reveal a proven sequence in which one symptom improved first and then caused others to recover.

Larger trials show the rapid effect is real

The new paper is small, but the broader acute-effect evidence is no longer small.

A 2026 JAMA Psychiatry meta-analysis combined 26 randomized clinical trials involving 1,166 patients with a major depressive episode.

After a single intravenous ketamine infusion, depressive symptoms were significantly lower than in control groups after four hours, 24 hours, three days and one week. The pooled effect was largest at four hours and remained substantial at 24 hours.

Another international patient-level analysis gives the results in more intuitive clinical terms.

Approximately one day after treatment, 45.5% of participants receiving ketamine met criteria for an antidepressant response, compared with 20.5% of controls. Remission occurred in 27.0% versus 13.0%.

At around one week, response was still present in 37.7% of ketamine-treated participants compared with 18.3% of controls, while remission rates were 25.0% versus 12.1%.

That does not mean ketamine works for everyone. Roughly half of treated patients did not meet response criteria after one infusion. But in treatment-resistant depression, where patients have already failed previous therapies, producing a clinically meaningful change within a day is unusual.

Suicidal thoughts can improve rapidly too

One of the most clinically important findings in the new analysis involved suicidal thinking.

The suicidal-thought item improved significantly within four hours.

That fits a much larger body of evidence. An individual-participant meta-analysis of controlled studies found that intravenous ketamine reduced suicidal ideation within one day, with benefits detectable across several subsequent assessments. Interestingly, the anti-suicidal effect remained statistically significant even after accounting for improvement in overall depression severity, suggesting that the relationship may not simply be a byproduct of feeling less depressed.

The 2026 meta-analysis of 26 randomized trials similarly found significant reductions in suicidal symptoms after intravenous ketamine.

This distinction needs careful wording. Reducing suicidal thoughts is clinically important, but it is not the same as proving that ketamine prevents suicide attempts or suicide deaths. The FDA prescribing information for intranasal esketamine explicitly notes that effectiveness in preventing suicide or reducing suicidal behavior has not been demonstrated.

Still, the speed matters. A treatment capable of changing severe suicidal thinking within hours represents a very different therapeutic tool from one whose effects may take several weeks to emerge.

How can an antidepressant work within hours?

Ketamine also forced neuroscience to rethink what an antidepressant has to do.

Traditional antidepressants largely alter monoamine signaling involving serotonin, norepinephrine or dopamine. Ketamine acts primarily on the glutamate system, particularly through NMDA receptor modulation.

One influential model proposes that ketamine blocks NMDA receptors on inhibitory interneurons, producing a brief increase in glutamate signaling. That can enhance activity through AMPA receptors and activate downstream pathways involving proteins such as BDNF and mTOR that regulate synaptic plasticity.

In simplified terms, the idea is not merely that ketamine changes the concentration of a neurotransmitter. It may temporarily push neural circuits into a state in which connections can reorganize unusually quickly.

Animal studies have linked ketamine to formation and restoration of dendritic spines and synaptic connections, particularly in prefrontal circuits affected by chronic stress.

But the mechanism is not settled. Ketamine metabolites, opioid signaling and other pathways may contribute, and researchers still disagree about which processes are essential for the antidepressant effect.

The dissociative experience is another unresolved question. Ketamine can produce alterations in perception and sense of self during treatment, but current evidence does not establish that these experiences are required for the antidepressant response.

The biggest problem is durability

Ketamine's speed is extraordinary. Its durability is less so.

A single infusion can produce benefits lasting days and sometimes longer, but the average effect weakens with time. This is why clinical protocols often investigate repeated induction infusions followed by maintenance treatment rather than assuming that one dose permanently resets depression.

That also changes the practical calculation. Repeated treatment means repeated monitoring, cost and exposure to adverse effects.

Acute effects can include dissociation, dizziness, nausea, sedation and temporary increases in blood pressure. Ketamine also has abuse potential, while frequent or heavy non-medical use has been associated with urinary-tract injury and other harms.

Intranasal esketamine illustrates how seriously regulators treat these risks. In the United States it is approved for treatment-resistant depression and can now be used as monotherapy or with an oral antidepressant, but administration occurs under healthcare supervision with post-dose monitoring.

Intravenous racemic ketamine remains an off-label psychiatric treatment in the United States even though its antidepressant efficacy is supported by numerous trials.

Ketamine may matter even beyond ketamine

Perhaps the most important legacy of ketamine is conceptual.

It demonstrated that the biology underlying severe depression can sometimes move much faster than psychiatry once expected.

The new symptom-level study strengthens that point. Four hours after treatment, improvement was already visible across almost the entire measured symptom profile rather than in one isolated feature of depression.

The challenge now is to understand what biological state ketamine creates, why some patients respond while others do not, and how the improvement can be extended without requiring indefinite repeated exposure to a dissociative drug.

If researchers can separate the rapid plasticity-producing mechanisms from ketamine's limitations, the ultimate result may not simply be better ketamine therapy.

It could be an entirely new generation of antidepressants designed to work on the timescale that ketamine proved was possible.

Scientific References & Further Reading


Disclaimer: This article is for informational purposes only and does not constitute medical advice. Ketamine and esketamine require clinical assessment and medical supervision and are not appropriate for unsupervised self-treatment.